Attovia Therapeutics Q2 Net Loss Widens

04:48 PM EDT, 09/02/2026 (MT Newswires) -- Attovia Therapeutics (ATTO) reported a Q2 net loss late Wednesday of $4.88 per diluted share, widening from the loss of $3.71 a year earlier. Two analysts polled by FactSet expected a loss of $0.63. Collaboration revenue in the three months ended June 30 was $450,000. Current cash, cash equivalents and marketable securities, including net proceeds from the initial public offering completed in August, total $305.4 million, enough to fund operations into 2030, the company said.